Cargando…

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gullapalli, Sneha, Remon, Jordi, Hendriks, Lizza E L, Lopes, Gilberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369644/ https://www.ncbi.nlm.nih.gov/pubmed/32764980 http://dx.doi.org/10.2147/OTT.S259308

Ejemplares similares

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review
por: Remon, Jordi, et al.
Publicado: (2021)

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
por: Le, Alexander D, et al.
Publicado: (2017)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Immunotherapy in small cell lung cancer: one step at a time: a narrative review
por: Dumoulin, Daphne W., et al.
Publicado: (2021)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
por: Shafique, Michael R, et al.
Publicado: (2018)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
por: Kawai, Shoko, et al.
Publicado: (2020)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Recent advances in non-small cell lung cancer targeted therapy; an update review
por: Araghi, Mahmood, et al.
Publicado: (2023)

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
por: Nakamura, Masakatsu, et al.
Publicado: (2020)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
por: Remon, Jordi, et al.
Publicado: (2016)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
por: Morgensztern, Daniel, et al.
Publicado: (2021)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
por: Liu, Yufei, et al.
Publicado: (2022)

Myositis induced by durvalumab in a patient with non‐small cell lung cancer: A case report
por: Kobayashi, Miyuki, et al.
Publicado: (2020)

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer
por: Pasquier, Corentin, et al.
Publicado: (2023)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
por: Capdevila, J., et al.
Publicado: (2023)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
por: Haaland, Benjamin, et al.
Publicado: (2014)

Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature
por: Kubo, Katsumaro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8qf6gb399qup4detth212d1v0e